Compare DexCom, Inc. (DXCM) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Oxford Lane Capital Corp — how do they compare? DexCom, Inc. trades at $77.82 (market cap $28.06B), while Oxford Lane Capital Corp trades at $9.04 (market cap $881.29M). The key difference: DexCom, Inc. is far larger — about 31.8× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 26.59% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | OXLC | |
|---|---|---|
Market Cap | $28.06B | $881.29M |
Sector | Health | Financials |
52-Week High | $89.53 | $20.75 |
52-Week Low | $54.84 | $8.15 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 26.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
OXLC trades at $9.035, down 1.04% with a bearish technical signal. The company reported negative earnings surprises in recent quarters, including a significant Q1 2026 miss, while maintaining a high dividend yield. Analyst sentiment is mixed with a 50% buy rating, but negative ROE and ROA raise concerns about financial health.
The outlook remains challenging with declining net asset value and operational cash flow deficits. While the high dividend yield attracts income investors, sustainability concerns persist given the negative profitability metrics and recent earnings underperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
